Tango Therapeutics (TNGX) Research & Development (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Research & Development of $33.5 million for Q1 2026, down 7.98% year-over-year from $36.4 million in Q1 2025, and up 4.46% quarter-over-quarter from $32.1 million in Q4 2025.
Tango Therapeutics (TNGX) Research & Development (2020 - 2026) Analysis & Trends
Tango Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $33.5 million for Q1 2026.
- In Q1 2026, Research & Development fell 7.98% year-over-year to $33.5 million; the TTM figure through Mar 2026 stood at $129.3 million (down 9.16% YoY), while the FY2025 annual figure was $132.2 million, down 8.17% from the prior year.
- Research & Development for Q1 2026 stood at $33.5 million, up from $32.1 million in the prior quarter.
- The five-year high for Research & Development was $38.7 million in Q2 2024, with the low at $23.7 million in Q2 2022.
- The 5-year median for Research & Development is $31.3 million (2023), against an average of $31.2 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 62.2% in 2022, then dropped 15.13% in 2025.
- Tango Therapeutics' Research & Development stood at $29.1 million in 2022, then gained by 7.73% to $31.3 million in 2023, then rose by 8.29% to $33.9 million in 2024, then dropped by 5.41% to $32.1 million in 2025, then gained by 4.46% to $33.5 million in 2026.
- Business Quant data shows TNGX's Research & Development at $33.5 million in Q1 2026, $32.1 million in Q4 2025, and $30.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 37.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.20 Mn |
| Mar 31, 2026 | 33.53 Mn |
| Dec 31, 2025 | 32.10 Mn |
| Sep 30, 2025 | 30.82 Mn |
| Jun 30, 2025 | 32.81 Mn |
| Mar 31, 2025 | 36.44 Mn |
| Dec 31, 2024 | 33.94 Mn |
| Sep 30, 2024 | 33.26 Mn |
| Jun 30, 2024 | 38.65 Mn |
| Mar 31, 2024 | 38.07 Mn |
| Dec 31, 2023 | 31.34 Mn |
| Sep 30, 2023 | 27.15 Mn |
| Jun 30, 2023 | 28.67 Mn |
| Mar 31, 2023 | 28.04 Mn |
| Dec 31, 2022 | 29.09 Mn |
| Sep 30, 2022 | 28.74 Mn |
| Jun 30, 2022 | 23.74 Mn |
| Mar 31, 2022 | 24.33 Mn |
| Dec 31, 2021 | 21.63 Mn |
| Sep 30, 2021 | 21.92 Mn |